Cloperastine

Cloperastine

Systematic (IUPAC) name
1-[2-[(4-Chlorophenyl)-phenyl-methoxy]ethyl]piperidine
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
Identifiers
CAS Number	3703-76-2 Y
ATC code	R05DB21 (WHO)
PubChem	CID: 2805
DrugBank	DB09002 N
ChemSpider	2703 Y
UNII	69M5L7BXEK Y
KEGG	D03557 Y
ChEMBL	CHEMBL415087 Y
Synonyms	HT-11
Chemical data
Formula	C20H24ClNO
Molecular mass	329.863 g/mol
SMILES Clc1ccc(cc1)C(OCCN2CCCCC2)c3ccccc3
InChI InChI=1S/C20H24ClNO/c21-19-11-9-18(10-12-19)20(17-7-3-1-4-8-17)23-16-15-22-13-5-2-6-14-22/h1,3-4,7-12,20H,2,5-6,13-16H2 Y Key:FLNXBVJLPJNOSI-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Cloperastine (INN) or cloperastin, also known as cloperastine hydrochloride (JAN) (brand names Hustazol, Nitossil, Seki) and cloperastine fendizoate (or hybenzoate), is an antitussive and antihistamine that is marketed as a cough suppressant in Japan, Hong Kong, and in some European countries. It was first introduced in 1972 in Japan, and then in Italy in 1981. The precise mechanism of action of cloperastine is not fully clear, but several different biological activities have been identified for the drug, of which include: ligand of the σ₁ receptor (K_i = 20 nM) (likely an agonist), GIRK channel blocker (described as "potent"), antihistamine (K_i = 3.8 nM for the H₁ receptor), and anticholinergic. It is thought that the latter two properties contribute to side effects, such as sedation and somnolence, while the former two may be involved in or responsible for the antitussive efficacy of cloperastine.

See also

• Clemastine
• Dimemorfan
• Tipepidine